Seres Therapeutics (NASDAQ: MCRB) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Seres Therapeutics to similar companies based on the strength of its dividends, analyst recommendations, risk, earnings, institutional ownership, valuation and profitability.
This is a breakdown of recent recommendations for Seres Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Seres Therapeutics Competitors||1243||3633||12170||259||2.66|
Seres Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 116.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.63%. Given Seres Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Seres Therapeutics is more favorable than its rivals.
Insider and Institutional Ownership
76.5% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 35.7% of Seres Therapeutics shares are owned by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Seres Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Seres Therapeutics Competitors||-5,322.40%||-107.79%||-36.67%|
Valuation and Earnings
This table compares Seres Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Seres Therapeutics||$21.77 million||-$91.57 million||-4.09|
|Seres Therapeutics Competitors||$271.74 million||-$19.68 million||77.95|
Seres Therapeutics’ rivals have higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Seres Therapeutics beats its rivals on 8 of the 12 factors compared.
About Seres Therapeutics
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.